A Study to Investigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2010-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effect of BIA 9-1067 on the levodopa pharmacokinetics when administered in combination with immediate release levodopa/carbidopa or levodopa/benserazide in Parkinson's Disease (PD) patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of BIA 9-1067 to Investigate Its Effect on Levodopa Pharmacokinetic

NCT01519284

Parkinson Disease

COMPLETED PHASE1

Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics

NCT02169414

Parkinson's Disease (PD)

COMPLETED PHASE1

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

NCT01568047

Parkinson's Disease

COMPLETED PHASE2

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" Phenomenon

NCT01568073

Parkinson's Disease

COMPLETED PHASE3

Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067

NCT02071810

Parkinson's Disease (PD)

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was a three-centre, double-blind, randomised, placebo-controlled, crossover study with four consecutive single-dose treatment periods in PD patients treated with immediate release 100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Sequence A

Treatment Sequence A Period 1 - 25 mg BIA 9-1067 Period 2 - 50 mg BIA 9-1067 Period 3 - 100 mg BIA 9-1067 Period 4 - Placebo

Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half

Group Type EXPERIMENTAL

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 25 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 50 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 100 mg single-dose

Placebo

Intervention Type DRUG

single-dose

Levodopa/Carbidopa

Intervention Type DRUG

Levodopa 100 mg Carbidopa 25 mg

Levodopa/Benzerazide

Intervention Type DRUG

Levodopa 100 mg Benzerazide 25 mg

Treatment Sequence B

Treatment Sequence B Period 1 - Placebo Period 2 - 25 mg BIA 9-1067 Period 3 - 50 mg BIA 9-1067 Period 4 - 100 mg BIA 9-1067

Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half

Group Type EXPERIMENTAL

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 25 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 50 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 100 mg single-dose

Placebo

Intervention Type DRUG

single-dose

Levodopa/Carbidopa

Intervention Type DRUG

Levodopa 100 mg Carbidopa 25 mg

Levodopa/Benzerazide

Intervention Type DRUG

Levodopa 100 mg Benzerazide 25 mg

Treatment Sequence C

Treatment Sequence C Period 1 - 100 mg BIA 9-1067 Period 2 - Placebo Period 3 - 25 mg BIA 9-1067 Period 4 - 50 mg BIA 9-1067

Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half

Group Type EXPERIMENTAL

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 25 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 50 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 100 mg single-dose

Placebo

Intervention Type DRUG

single-dose

Levodopa/Carbidopa

Intervention Type DRUG

Levodopa 100 mg Carbidopa 25 mg

Levodopa/Benzerazide

Intervention Type DRUG

Levodopa 100 mg Benzerazide 25 mg

Treatment Sequence D

Treatment Sequence D Period 1 - 50 mg BIA 9-1067 Period 2 - 100 mg BIA 9-1067 Period 3 - Placebo Period 4 - 25 mg BIA 9-1067

Levodopa/Carbidopa combination were given to half of the volunteers and Levodopa/Benzerazide to the other half

Group Type EXPERIMENTAL

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 25 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 50 mg single-dose

BIA 9-1067

Intervention Type DRUG

BIA 9-1067 - 100 mg single-dose

Placebo

Intervention Type DRUG

single-dose

Levodopa/Carbidopa

Intervention Type DRUG

Levodopa 100 mg Carbidopa 25 mg

Levodopa/Benzerazide

Intervention Type DRUG

Levodopa 100 mg Benzerazide 25 mg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIA 9-1067

BIA 9-1067 - 25 mg single-dose

Intervention Type DRUG

BIA 9-1067

BIA 9-1067 - 50 mg single-dose

Intervention Type DRUG

BIA 9-1067

BIA 9-1067 - 100 mg single-dose

Intervention Type DRUG

Placebo

single-dose

Intervention Type DRUG

Levodopa/Carbidopa

Levodopa 100 mg Carbidopa 25 mg

Intervention Type DRUG

Levodopa/Benzerazide

Levodopa 100 mg Benzerazide 25 mg

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

OPC, Opicapone OPC, Opicapone OPC, Opicapone PLC Sinemet Madopar®/Restex®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female of non-childbearing potential (by reason of surgery or postmenopausal);
* Aged between 30 and 75 years, inclusive;
* A diagnosis of PD according to the UK PDS Brain Bank diagnostic criteria (bradykinesia and at least one of the following: muscular rigidity, rest tremor and postural instability);
* Predictable signs of end-of-dose deterioration despite "optimal" levodopa/carbidopa or levodopa/benserazide therapy;
* Been treated with a stable regimen of 3 to 8 doses of standard release 100 mg/25 mg levodopa/carbidopa or 100 mg/25 mg levodopa/benserazide per day within at least 1 week prior to randomisation;
* Modified Hoehn and Yahr stage of less than 5 in the off-state;
* Mean duration of OFF stage ≥ 1.5 h during waking hours (based on historical information);
* Concomitant anti-Parkinsonian medication (other than apomorphine, entacapone or tolcapone) in stable doses for at least 4 weeks prior to randomisation;
* Results of clinical laboratory tests acceptable by the investigator (not clinically significant for the well-being of the subject or for the purpose of the study);
* Able and willing to give written informed consent.

Exclusion Criteria

* Non-idiopathic parkinsonism (atypical parkinsonism, symptomatic parkinsonism, Parkinson-plus syndrome);
* Treated with levodopa/carbidopa or levodopa/benserazide in a 10:1 ratio, or with levodopa/carbidopa in a controlled-release formulation;
* Treated with entacapone, tolcapone, neuroleptics, antidepressants (except serotonin-specific reuptake inhibitors or imipramines \[desipramine, imipramine, clomipramine and amitriptyline\]), monoamine oxidase inhibitors (except selegiline up to 10 mg/day in oral formulation or 1.25 mg/day in buccal absorption formulation or rasagiline up to 1 mg/day) or antiemetics (except domperidone) within 4 weeks prior to randomisation;
* Treated with apomorphine within 7 days prior to randomisation;
* Treated with any investigational product within 2 months prior to randomisation (or within 5 half-lives, whichever is longer);
* A psychiatric or any medical condition that might place him/her at increased risk or interfere with assessments;
* Known hypersensitivity to any of the ingredients of the investigational products;
* A history of abuse of alcohol, drugs or medications within the last 2 years;
* A clinically relevant ECG abnormality;
* A history or current evidence of heart disease, including but not limited to myocardial infarction, angina, congestive heart failure and cardiac arrhythmia;
* Unstable concomitant disease being treated with changing doses of medication;
* A history or current evidence of any relevant disease in the context of this study, i.e., with respect to the safety of the subject (e.g., hepatic or renal impairment) or related to the study conditions;
* A test positive for the human immunodeficiency viruses (HIV) 1 or 2 antibodies, or hepatitis B surface antigen (HBsAg), or hepatitis C antibody (HCVAb);
* Donated blood or received blood or blood products within the 6 months prior to randomisation;
* Pregnant, breast-feeding or of childbearing potential;
* Other condition or circumstance that, in the opinion of the investigator, may compromise the subject's ability to comply with the study protocol.

Minimum Eligible Age

30 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No